| Date | Title | | | 05/16/12 | Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease|
SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling moderate to s... |
|  | | 05/01/12 | Rigel Announces First Quarter 2012 Financial Results| SOUTH SAN FRANCISCO, Calif., May 1, 2012 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2012.
For the first quarter of 2012, Rigel reported a net loss of $23.2 million, or $0.32 per share, compared to a net loss of $20.8 million, or $0.40 per share, in the first quarter of 2011. Weighted average shares outstanding for the first quarters of 2012 and 2011 were 71.4 million and 52.3 million, respectively... |
| | | 03/06/12 | Rigel Announces Fourth Quarter and Year End 2011 Financial Results|
SOUTH SAN FRANCISCO, Calif., March 6, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2011. For the fourth quarter of 2011, Rigel reported a net loss of $25.8 million, or $0.36 per share, compared to a net loss of $17.2 million, or $0.33 per share, in the fourth quarter of 2010. Weighted average shares outstanding for the fourth quarter of 2011 and 2010 were 71.2 million and 52.2 million, resp... |
| | | 02/23/12 | Rigel Announces Participation at Two Investor Conferences|
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will participate at two upcoming investor conferences. Details of the events are as follows:
(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)
Citi 2012 Global Health Care Conference
Date: Monday, February 27 at 1:30 p.m... |
| | | 01/05/12 | Rigel Announces Initiation of Clinical Trials in Two Immunology Programs| Robust Pipeline will be the Company's focus at J.P. Morgan Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) today announced that two of its lead product candidates entered clinical trials during the fourth quarter of 2011. The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhi... |
| |
|
rigel in the news
